This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 1 of 1 for:    PCS-X
Previous Study | Return to List | Next Study

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04070209
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : January 24, 2024
Information provided by (Responsible Party):
Dr. Tamim Niazi, Sir Mortimer B. Davis - Jewish General Hospital

Brief Summary:
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.

Condition or disease Intervention/treatment Phase
Metastatic Prostate Cancer Castration-resistant Prostate Cancer Drug: Darolutamide (BAY1841788) Radiation: SBRT Phase 2

Detailed Description:

Metastases-directed therapy with stereotactic body radiation therapy (SBRT) is emerging as a new treatment option for solid tumor patients with a limited number of metastases (< 5) at the time of recurrence/progression, so called oligoprogression therapy. As such, oligoprogression is defined as prostate cancer patients with castration resistance and no metastases (M0CRPC) who are receiving ADT and new generation hormonal therapy (enzalutamide, apalutamide or darolutamide) as standard of care, and who are then progressing to oligometastases. The new generation hormonal therapy used in this study will be darolutamide (ODM-201). The rationale behind this approach has been to delay the start of palliative systemic therapies that are most often toxic and associated with a negative impact on patient's quality of life, as well as being more costly. However, to date, there are no prospective published data or ongoing studies that are looking into non metastatic castration resistant prostate cancer (M0CRPC) patients who progress to oligometastases (oligoprogression). To this end, we are proposing this pilot phase II trial to assess the impact of SBRT on radiological progression-free survival (RPFS) of M0CRPC patients who are receiving darolutamide and progress to oligometastatic disease (oligoprogression).

Prostate cancer patients with castration resistance and no metastases (M0CRPC) diagnosed by bone scan and CT scan or MRI will be recruited in this phase II and initiate darolutamide while continuing on ADT (Part 1 of the study), if not receiving darolutamide prior to study entry already. Patients who then progress to wide spread metastases or metastases situated at locations not amenable to ablative therapy will be excluded and treated with second line therapy as per the treating physician. Patients with oligoprogression (< 5 mets) and amenable to ablative therapy will be then treated with SBRT or surgery as an ablative therapy if SBRT is not feasible (Part 2 of the study). All patients will continue to receive non-interrupted LHRH agonist, PSA testing every 6-12 weeks and re-imaging every 6 months. Imaging will also be repeated at the appearance of symptoms or at PSA progression, whichever occurs first and this schedule continues until disease progression.

This is the first pilot phase II trial assessing the response of SBRT layered on darolutamide on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression. This phase II will consist of 66 M0CRPC patients treated with darolutamide, of which we anticipate 48 will be eligible for SBRT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: A Pilot Phase II Trial
Actual Study Start Date : October 19, 2020
Estimated Primary Completion Date : November 2027
Estimated Study Completion Date : November 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Darolutamide (BAY1841788)+ SBRT

CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).

Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT

Drug: Darolutamide (BAY1841788)
Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
Other Name: ODM-201

Radiation: SBRT
SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.

Primary Outcome Measures :
  1. Radiographic Progression-free Survival [ Time Frame: 5 years ]
    Time from first day of SBRT until confirmed second radiological progression or start of new antineoplastic therapy

Secondary Outcome Measures :
  1. Functional Assessment of Cancer Therapy-Prostate [ Time Frame: 5 years ]
    Evaluate the impact of the treatment on the patient's quality of life using the FACT-P questionnaire

  2. Quality of Life - Fatigue [ Time Frame: 5 years ]
    Evaluate the impact of the treatment on the patient's quality of life using the Brief Fatigue Inventory (BFI) questionnaire

  3. Quality of Life - Pain [ Time Frame: 5 years ]
    Evaluate the impact of the treatment on the patient's quality of life using the Brief Pain Inventory (BPI) questionnaire

  4. Toxicity of ODM-201 [ Time Frame: 5 years ]
    To determine acute and late toxicity due to ODM-201, scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

  5. Time to Subsequent Systemic Antineoplastic Therapy [ Time Frame: 5 years ]
    Time to the administration of subsequent antineoplastic systemic therapy

  6. PSA response [ Time Frame: 5 years ]
    PSA value and onset of biochemical failure will be recorded

  7. Overall Survival [ Time Frame: 5 years ]
    Time from randomization until death from any cause

  8. Disease Specific Survival [ Time Frame: 5 years ]
    Time from randomization until death due to prostate cancer

  9. Time to Skeletal-related Event (SRE) [ Time Frame: 5 years ]
    Date of first SRE will be recorded

  10. Local Control [ Time Frame: 5 years ]
    To evaluate the impact of SBRT on oligometastases progression by radiographic imaging or the start of new antineoplastic therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria (Part 1):

  • Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features;
  • M0CRPC at study entry defined as follows:

    1. Ongoing androgen deprivation therapy with a LHRH agonist or bilateral orchiectomy (i.e., surgical or medical castration);
    2. Serum testosterone level ≤ 1.7 nmol/L (50 ng/dL) at the Screening visit;
    3. PSA progression defined by a minimum of two subsequent rising PSA levels with an interval of ≥ 1 week between each determination. Patients who received an anti-androgen must have progression after withdrawal (≥ 4 weeks since last flutamide or ≥ 6 weeks since last bicalutamide or nilutamide). The PSA value at the Screening visit should be ≥ 2 μg/L (2 ng/mL)
    4. PSA doubling time of 10 months or less,
    5. M0 assessed by conventional imaging (CT/MRI + bone scan).

NOTE: If darolutamide started prior to study entry, evidence of inclusion criteria 1-5 listed above prior to start of darolutamide must be submitted to determine study eligibility

  • Prior cytotoxic chemotherapy for prostate cancer in adjuvant setting post radical therapy is allowed;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or Karnofsky performance status of > 80% or higher;
  • Estimated life expectancy of ≥ 6 months;
  • Ability to swallow the study drug whole and comply with study.
  • Patients should not have been previously exposed to other ARATs (Abiraterone, Enzalutamide, Apalutamide)

Inclusion Criteria (Part 2):

  • ≤ 5 metastatic sites (on conventional imaging);
  • ≤ 4 tumors within any given organ system, excluding brain (e.g. up to 4 bone metastases, or 4 lung metastases);
  • All sites of disease must be amenable to SBRT with no history of the metastases being irradiated (radiation exposure prior to the development of the metastases is permitted as long as the radiation exposure was not intended for the metastases. For example, if there is prior pelvic radiation to the prostate and a subsequent iliac metastasis develops within the previously irradiated pelvic radiation field, then the iliac metastasis would be eligible per the institution policy and practice);
  • In the case of a suspicious lesion in an unusual location such as lung or thoracic lymph nodes (without other abdominal lymph nodes), a confirmatory imaging or biopsy is strongly recommended;

Exclusion Criteria (Part 1):

  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;
  • Presence of distant metastasis, including previously treated (clinical stage M1) is exclusive, however isolated pelvic nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion criteria.
  • History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer;
  • Absolute neutrophil count < 1,500/μL, platelet count < 100,000/μL, or hemoglobin < 5.6 mmol/L (9 g/dL) at the Screening visit (NOTE: patients may not have received any growth factors within 7 days or blood transfusions within 28 days of the hematologic laboratory values obtained at the Screening visit);
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal and total bilirubin > 1.5 times the upper limit of normal at the Screening visit;
  • Creatinine > 2 times the upper limit of normal at the Screening visit;
  • Clinically significant cardiovascular disease including:

    1. Stroke or myocardial infarction within 6 months;
    2. Uncontrolled angina within 6 months;
    3. Coronary/peripheral artery bypass graft within 6 months;
    4. Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patients with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within three months results in a left ventricular ejection fraction that is ≥ 45%;
    5. History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place;
    6. Uncontrolled hypertension as indicated by a resting systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg at screening. Patients may be re-screened after adjustments of antihypertensive medications;
    7. Bradycardia as indicated by a heart rate of < 50 beats per minute on the Screening ECG;
  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months);
  • Major surgery within 4 weeks of enrollment (Day 1 Visit);
  • Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease
  • Use of opiate analgesics (eg. morphine, fentanyl, etc.) for pain from prostate cancer within 4 weeks of enrollment (Day 1 visit). This does not apply to non-morphine drugs like codeine;
  • Radiation therapy for treatment of the primary tumor within 3 weeks of enrollment (Day 1 visit);
  • Radiation or radionuclide therapy for treatment of metastasis;
  • Primary disease not treated;
  • Hormone naïve prostate cancer patients;
  • Treatment with estrogens or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 4 weeks of enrollment (Day 1 visit);
  • Treatment with systemic biologic therapy for prostate cancer (other than approved bone targeted agents and GnRH-analogue therapy) or other agents with anti-tumour activity within 4 weeks of enrollment (Day 1 visit);
  • Prior use of an investigational agent that blocks androgen synthesis (e.g., abiraterone acetate, enzalutamide, Apalutamide, TAK-700, TAK-683, TAK-448) or targets the androgen receptor (e.g., BMS 641988) on clinical trials;
  • Known or suspected contraindications or hypersensitivity to darolutamide or GnRH agonists or any of the components of the formulations;
  • Use of an investigational agent within 4 weeks of enrollment (Day 1 visit);
  • Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within four weeks of enrollment (Day 1 visit);
  • Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data;
  • Unable to swallow study medications and comply with study requirements

Exclusion criteria (Part 2):

  • Known or suspected brain metastasis or active leptomeningeal disease;
  • > 5 metastasis;
  • More than 4 metastasis in the same organ;
  • Patients considered for SBRT in previous history of radiation therapy to the same area.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04070209

Layout table for location contacts
Contact: Paola Diego 514-340-8222 ext 24404

Layout table for location information
Canada, Alberta
Prostate Cancer Centre Recruiting
Calgary, Alberta, Canada, T2V 1P9
Contact: Lora Mendoza   
Principal Investigator: Geoffrey Gotto, MD         
Canada, Nova Scotia
Centre of Applied Urology Research Recruiting
Halifax, Nova Scotia, Canada, B3H 2Y9
Contact: Kelly Macdonald   
Principal Investigator: Ricardo Rendon, MD         
Canada, Ontario
St. Joseph's Healthcare Hamilton Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: Marie Therese Balart   
Principal Investigator: Bobby Shayegan, MD         
Canada, Quebec
Service d'urologie et Centre de la prostate Recruiting
Longueuil, Quebec, Canada, J4V 2H3
Contact: Joanie Valcourt   
Principal Investigator: Elie Antebi, MD         
Centre hospitalier de l'Université de Montréal (CHUM) Recruiting
Montreal, Quebec, Canada, H2X 3E4
Contact: Mom Phat   
Principal Investigator: Guila Delouya, MD         
Hôpital Maisonneuve-Rosemont Recruiting
Montréal, Quebec, Canada, H1T 2M4
Contact: Lys Fernet   
Principal Investigator: Peter Vavassis, MD         
Sir Mortimer JGH Recruiting
Montréal, Quebec, Canada, H3T 1E2
Contact: Paola Diego    514-340-8222 ext 24404   
Principal Investigator: Tamim Niazi, MD         
L'Hôtel-Dieu de Québec (CHUQ) Recruiting
Québec city, Quebec, Canada, G1R 2J6
Contact: Josee Allard   
Principal Investigator: Andrey-Guy Martin, MD         
Hôpital Fleurimont (CHUS) Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Cynthia Ladouceur   
Principal Investigator: Myriam Bouchard, MD         
Centre hospitalier affilié universitaire régional (CHAUR) Recruiting
Trois-Rivières, Quebec, Canada, G8Z 3R9
Contact: Julie Samson   
Principal Investigator: Vincent Trudeau, MD         
Sponsors and Collaborators
Sir Mortimer B. Davis - Jewish General Hospital
Layout table for investigator information
Principal Investigator: Tamim Niazi, MD Jewish General Hospital
Layout table for additonal information
Responsible Party: Dr. Tamim Niazi, Principal Investigator, Sir Mortimer B. Davis - Jewish General Hospital Identifier: NCT04070209    
Other Study ID Numbers: PCS X
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: January 24, 2024
Last Verified: January 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases